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SUMMARY

The role of chromatin structure in lineage commitment of multipotent hematopoietic progenitors
(HPCs) is presently unclear. We show here that
CD34+ HPCs possess a post-replicative chromatin
globally devoid of the repressive histone mark
H3K27me3. This H3K27-unmodified chromatin is
required for recruitment of lineage-determining transcription factors (TFs) C/EBPa, PU.1, and GATA-1 to
DNA just after DNA replication upon cytokine-induced
myeloid or erythroid commitment. Blocking DNA
replication or increasing H3K27me3 levels prevents
recruitment of these TFs to DNA and suppresses
cytokine-induced erythroid or myeloid differentiation.
However, H3K27me3 is rapidly associated with
nascent DNA in more primitive human and murine
HPCs. Treatment of these cells with instructive cytokines leads to a significant delay in accumulation of
H3K27me3 in nascent chromatin due to activity of
the H3K27me3 demethylase UTX. Thus, HPCs utilize
special mechanisms of chromatin modification for
recruitment of specific TFs to DNA during early stages
of lineage specification.
INTRODUCTION
The process of hematopoiesis is regulated by a network of transcription factors (TFs) acting cooperatively or antagonistically on
multipotent or lineage-restricted hematopoietic progenitors/
precursors (Friedman, 2007; Orkin and Zon, 2008). A critical
step in differentiation of hematopoietic stem cells (HSCs) is the
commitment of multipotent progenitors to lineage-restricted
progenitors. The prevailing explanation for lineage commitment
is that it depends on stochastic fluctuation in the levels of

competing lineage-determining TFs that activate a lineage-specific gene expression program while suppressing those leading
to alternative choices (Cantor and Orkin, 2001; Chang et al.,
2008; Graf and Enver, 2009; Orkin, 2000; Till et al., 1964).
However, recent studies support an ‘‘instructive’’ model
whereby lineage-specific cytokines (e.g., granulocyte-colony
stimulating factor [G-CSF], macrophage-colony stimulating factor [M-CSF], or erythropoietin [EPO]) act on multipotent progenitors to activate lineage-specific master TFs and promote the
expansion of the myeloid or the erythroid lineage (Grover et al.,
2014; Mossadegh-Keller et al., 2013; Rieger et al., 2009). On
the other hand, single-cell transcription profiling of primitive
hematopoietic progenitors purified based on the expression of
surface markers commonly used to define a ‘‘multipotent state’’
has revealed that truly multipotent progenitors may not exist and
that these cells are highly heterogeneous and may be already
committed to a specific lineage (Notta et al., 2016; Paul et al.,
2015; Perié et al., 2015). Collectively, these findings raise the
possibility that both ‘‘stochastic’’ and ‘‘instructive’’ mechanisms
contribute to lineage specification and that ‘‘instructive’’ cytokines function in this process earlier than previously thought.
Specification of myeloid cell fate requires the TFs PU.1 and
C/EBPa, but macrophage versus granulocytic differentiation
depends on the relative levels of PU.1 or C/EBPa, respectively
(Dahl et al., 2003; Iwasaki et al., 2006; Laslo et al., 2006). EPO
has an instructive role for erythroid commitment of stem cell-enriched cell subsets, a process that is, at least in part, GATA-1dependent (Cui et al., 2009; Grover et al., 2014).
While C/EBPa, PU.1, or GATA-1 can promote unilineage differentiation by inducing new transcriptional programs, it remains
unclear how these TFs cause changes in the existing epigenetic
maintenance system. Upon EPO-induced erythroid differentiation of the multipotent CD133+CD34+ HPCs global changes in
gene expression are in general correlated with the changes in
association of the H3K4me3 or the H3K27me3 positive or negative histone marks respectively, although some ‘‘bivalent’’ genes
lost or retained both marks (Cui et al., 2009). These changes in
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chromatin marks and gene expression profiles were detected in
cells induced to erythroid differentiation for 9–11 days (Cui et al.,
2009), suggesting that they may not reflect ‘‘commitment’’ to differentiation toward a specific lineage that is likely to occur much
earlier. The dynamics of certain chromatin modifications was
also globally examined in purified subsets representing distinct
stages of murine hematopoietic differentiation (Lara-Astiaso
et al., 2014). The results of this analysis are consistent with the
existence of a transcription factor network that may control chromatin dynamics and lineage specification.
However, these studies are mostly correlative and do not provide a mechanistic explanation for how changes in transcriptional programs and chromatin structure occur. An essential
issue is how newly induced TFs overcome the existing chromatin-based barrier when they are recruited to new target
genes. It is also not clear whether chromatin marks play any
role in allowing the access of lineage-determining TFs to the
regulatory regions of the genes essential for differentiation and
whether chromatin changes occur before or after changes in
the transcriptional programs. Thus, at present we only know
the end results of lineage specification, but there is insufficient
information on the molecular mechanisms that allow these
changes during the early stages of lineage commitment. Knowledge of these mechanisms is essential in order to control lineage
specification and may be important in understanding the mechanisms responsible for the differentiation arrest of leukemic
cells.
In our study, we examined the assembly of chromatin in vivo
at single-cell and gene-specific levels following DNA replication. We show that CD34+ HPCs possess a post-replicative
chromatin globally devoid of the repressive histone mark
H3K27me3. This type of chromatin is required for recruitment
of C/EBPa, PU.1, and GATA-1 to DNA just after DNA replication
upon treatment with instructive cytokines to induce erythroid or
myeloid commitment. Blocking DNA replication or increasing
H3K27me3 levels prevents recruitment of these TFs to DNA
and suppresses cytokine-induced erythroid or myeloid differentiation. By contrast, H3K27me3 is rapidly associated with
nascent DNA in primitive CD34+CD38 HPCs, and treatment
of these cells with instructive cytokines leads to a period of
de-condensed, H3K27me3-unmodified nascent chromatin
due to increase of the H3K27me3 demethylase UTX. These
studies suggest that HPCs utilize special mechanisms of chromatin alteration for recruitment of specific TFs to DNA during
initial stages of differentiation.
RESULTS
Dynamics of H3K27me3 Chromatin during Lineage
Specification of Multipotent Hematopoietic Progenitors
Our previous studies suggested that accumulation of major histone modifications, including H3K27me3, following DNA replication is delayed by at least 1 hr in cells of developing Drosophila
embryos (Petruk et al., 2012). This suggests that modified histones do not directly carry epigenetic information and implies
that post-replicative chromatin may transiently consist of nucleosomes lacking H3K27me3 marks, which were not detected
previously in bulk chromatin (Petruk et al., 2012). Because the
296 Cell Reports 19, 295–306, April 11, 2017

absence of repressive H3K27me3 correlates with low density
of nucleosomes (Bell et al., 2010; Shlyueva et al., 2014; Yuan
et al., 2012), such unmodified histones may create a very
de-condensed conformation of post-replicative chromatin. We
hypothesize that this unusual H3K27me3-unmodified post-replicative chromatin may be essential during early stages of differentiation to create more favorable conditions for binding of newly
induced lineage-determining TFs.
First, we examined whether chromatin lacking H3K27me3 is a
common feature of human HPCs. We used the chromatin assembly assay (CAA) (Petruk et al., 2012) to examine the rate of
accumulation of H3K27me3 in human cord blood and G-CSFmobilized CD34+ progenitor cells. DNA in proliferating CD34+
cells was pulse-labeled with 5-ethynyl-2’-deoxyuridine (EdU),
which was then conjugated with biotin, and the proximity of
H3K27me3 to nascent DNA was assessed by the proximity ligation assay (PLA, Olink) using antibodies to biotin and H3K27me3.
Following CAA, cells were immunostained with EdU and DAPI to
assess the specificity of the assay. We found that in CD34+ cells
H3K27me3 accumulates significantly at nascent DNA only at
around 2 hr following DNA replication (Figure 1A).
Then, we examined whether the accumulation of post-replicative H3K27me3 undergoes changes during lineage specification
of HPCs. Cells were induced toward granulocytic or macrophage
differentiation by treatment with G-CSF or M-CSF, respectively,
and accumulation of H3K27me3 on nascent DNA was analyzed
after 15 min of EdU incorporation. No H3K27me3 was detected
on 15 min EdU-labeled nascent DNA at 6 hr and 12 hr after
G-CSF or M-CSF treatment. However, we detected significant
accumulation of H3K27me3 on 15 min EdU-labeled nascent
DNA at 24 hr after induction with each cytokine (Figure 1B).
Thus, irrespective of lineage choice, the H3K27me3-unmodified
post-replicative chromatin structure of HPCs persists for at least
12 hr following exposure to instructive cytokines. The post-replicative structure of chromatin may become more compact 1 day
into HPC differentiation.
Lineage-Determining Transcription Factors Bind to
Post-replicative H3K27me3-Unmodified Chromatin
upon Cytokine-Induced Lineage Commitment
Induction with ‘‘instructive’’ cytokines leads to expression of
key TFs that specifically change the transcriptional landscape
of differentiating HPCs. It is not known whether there is a specific
mechanism that allows these TFs to bind to DNA during cell
differentiation. Previous EMSA analyses showed that C/EBPa
is associated with promoters of target genes after 3 days of
G-CSF-induced differentiation of myeloid precursor cells (Iida
et al., 2008). To further investigate this, we used the CAA to
examine the association of C/EBPa, PU.1, and GATA-1 with
DNA following induction with G-CSF, M-CSF, and EPO, respectively, of cord blood or G-CSF-mobilized peripheral blood CD34+
cells. As expected, cytokine treatment induced a decrease in
CD34 positivity first detected at 72 hr and the simultaneous
appearance of lineage-specific differentiation markers (Figures
2A and S1). C/EBPa and PU.1 are first detected on the 1 hr
EdU-labeled nascent DNA at 6 hr following treatment with
G-CSF and M-CSF, respectively, while GATA-1 is detected at
12 hr following induction with EPO (Figure 2B). Thus, irrespective

Figure 1. Kinetics of H3K27me3 Accumulation following DNA Replication in Cytokine-Treated CD34+ HPCs
(A) Left: accumulation of H3K27me3 on nascent DNA of G-CSF-mobilized CD34+ HPCs. DNA was labeled with EdU for 15 min and chased to 1, 2, and 4 hr.
Following conjugation with biotin, CAA was performed between nascent DNA (biotin) and H3K27me3. Red, PLA; green, EdU (biotin); blue, DAPI. Lower panels
show PLA signals only. Right: quantification of the results of CAA experiments shown to the left by counting the number of PLA signals per EdU-labeled nuclei in
50 cells/each of the three independent experiments.
(B) Left: accumulation of post-replicative H3K27me3 during differentiation of CD34+HPCs. Cells were induced for myeloid differentiation with either G-CSF (upper
panels) or M-CSF (lower panels) for 0, 6, 12, and 24 hr. DNA was labeled with EdU for 15 min and CAA performed between EdU (biotin) and H3K27me3. Red, PLA;
green, EdU (biotin); blue, DAPI. Lower panels show PLA signals only. Right: quantification of the results of CAA experiments shown to the left by counting the
number of PLA signals per EdU-labeled nuclei in 50 cells/each of the three independent experiments. Error bars represent ± SD. p Values were determined by
ANOVA. ns, non-significant; *p < 0.05.

of the induced differentiation program, specific TFs are recruited
to DNA at 6–12 hr following treatment with lineage-determining
cytokines, much earlier than previously thought. Importantly,
the time of recruitment is within the period in which cytokinetreated HPCs carry the H3K27me3-unmodified post-replicative
chromatin.
These results are consistent with our hypothesis that recruitment of key lineage-determining TFs to DNA may be facilitated
by the low-nucleosome density of post-replicative chromatin
devoid of H3K27me3. This state of histone H3K27 modification
may result from the activities of H3K27me3-specific homologous
histone demethylases (KDMs) UTX and JMJD3. To examine this,
we inhibited the activities of these KDMs by treatment with
GSKJ4, a small molecule inhibitor of these enzymes (Kruidenier
et al., 2012). Then, cord blood CD34+ cells were induced for 12 hr
to myeloid or erythroid differentiation with G-CSF or M-CSF,

or EPO, respectively, and accumulation of H3K27me3 was
analyzed by CAA on nascent DNA labeled with EdU for 15 min.
Similar to previous results with G-CSF and M-CSF (Figure 1),
we did not detect H3K27me3 on 15 min EdU-labeled nascent
DNA following 12 hr induction with EPO (Figure 3A, upper
panels). Treatment of cells with GSKJ4 leads to significant
accumulation of H3K27me3 on nascent DNA labeled with EdU
for 15 min following 12 hr induction of these cells with all
three lineage-determining cytokines (Figure 3A, lower panels).
Then, we asked whether faster accumulation of post-replicative
H3K27me3 affects recruitment of induced TFs in these cell lineages. The strong recruitment of C/EBPa, PU.1, and GATA-1,
detected at 12 hr following induction with the corresponding
cytokine (Figures 2 and 3A, upper panels), was completely
blocked by treatment with GSKJ4 (Figure 3A, lower panels).
This suggests that the H3K27me3-unmodified post-replicative
Cell Reports 19, 295–306, April 11, 2017 297

Figure 2. Kinetics of Recruitment of Lineage-Determining TFs C/EBPa, PU.1, and
GATA-1 to DNA
(A) In vitro differentiation of G-CSF-mobilized
CD34+ cells. Cells were treated with G-CSF,
M-CSF, or EPO for the indicated times. Differentiation was assessed by flow cytometry for lineage-specific markers.
(B) G-CSF-mobilized CD34+ HPCs were induced
toward myeloid or erythroid differentiation by
treatment with G-CSF, M-CSF, or EPO, respectively, for 6, 12, and 24 hr. DNA was pulse-labeled
with EdU for 15 min and chased to 1 hr. CAA was
performed between nascent DNA (biotin) and
C/EBPa, PU.1, or GATA-1. red, PLA; green, EdU
(biotin), blue, DAPI. Lower panel shows PLA signals only. Bottom: quantification of the results of
CAA experiments shown above by counting the
number of PLA signals per EdU-labeled nuclei in
50 cells/each of the three independent experiments. Error bars represent ± SD. p Values were
determined by ANOVA. *p < 0.05.

CD15 differentiation antigens (27.5 versus
53.2%) (Figure S2B). Of interest, at the
72 hr time point chosen for the analysis
of erythroid differentiation markers, CD34
positivity was essentially identical in cells
treated with EPO only or with GSKJ4 and
EPO (Figure S3). Thus, the H3K27me3 unmodified structure of nascent chromatin is
essential for lineage specification of HPCs.

chromatin is favorable for recruitment of C/EBPa, PU.1, and
GATA-1 to their DNA binding sites.
By contrast, maintaining H3K27me3 accumulated on nascent
chromatin may prevent association of key lineage-inducing
TFs to DNA, leading to decreased induction of the gene targets
of these TFs, and may ultimately result in a block of lineage
specification.
In line with this, expression of GATA-1 was not affected by
GSKJ4 treatment of EPO-stimulated CD34+ cells (Figure 3B); by
contrast, inhibiting GATA-1 binding to DNA (Figure 3A, right panel)
led to a marked decrease in the expression of GATA-1-regulated
genes (Welch et al., 2004) and a complete block of EPO-induced
differentiation revealed by loss of erythroid marker expression
(Figures 3C and 3D). Likewise, treatment with GSKJ4 had no effect
on G-CSF-induced C/EBPa expression but suppressed cytokineinduced myeloid differentiation of mobilized CD34+ cells, as indicated by its ability to block the increase in the expression of several
C/EBPa-regulated genes (Figure S2A). Moreover, compared to
treatment with G-CSF only, co-treatment with GSKJ4 resulted in
a less differentiated phenotype revealed by the marked decrease
in the proportion of cells co-expressing the CD33 and the
298 Cell Reports 19, 295–306, April 11, 2017

C/EBPa Is Recruited to Postreplicative Chromatin in the
S Phase of the Cell Cycle
It is not well established when lineagespecific TFs are recruited to DNA in undifferentiated cells; while some studies propose that this occurs
during the G1 phase (Kapinas et al., 2013; Murray and Kirschner,
1989; Singh and Dalton, 2009), other studies dispute this idea
(Filipczyk et al., 2007; Jonk et al., 1992; Li et al., 2012; Mummery
et al., 1987). To examine this, CD34+ cells were labeled with EdU
and then treated with G-CSF for 24 hr. This allows detection of
C/EBPa on labeled DNA (Figure 4A, left). However, blocking
S phase entry in these cells by treatment with thymidine (Figure 4B, left) prevented the accumulation of C/EBPa on EdUlabeled DNA (Figure 4A and 0 hr). Release from thymidine block
for 2 and 4 hr allows significant re-initiation of DNA replication
(Figure 4B, middle and right) and leads to efficient accumulation
of C/EBPa on nascent DNA (Figure 4A, 2 and 4 hr). These findings support our hypothesis that the initial association of TFs
with DNA following cytokine treatment occurs primarily during
early post-replicative periods in S phase.
Accumulation of H3K27me3-Modified Chromatin in
Primitive HPCs
To assess whether the H3K27me3-unmodified chromatin also
exists in more primitive HPCs, we examined the loading of

H3K27me3 on nascent DNA in the CD90+ subpopulation of
CD34+ cells. Surprisingly, CD90+ cells exhibited high accumulation of H3K27me3 on DNA labeled with EdU for only 15 min (Figure 5A). Because most CD34+CD90+ cells are contained within
the CD34+CD38 subset, we confirmed this fast mode of accumulation of H3K27me3 in uninduced CD34+CD38 cells (Figure 5B). However, 12 hr induction of CD34+CD38 cells with
G-CSF or M-CSF led to slow accumulation of post-replicative
H3K27me3 (Figure 5B). Further treatment for 24 hr restored
fast accumulation of post-replicative H3K27me3. This suggests
that compared to CD34+cells, most of which carry H3K27me3unmodified post-replicative chromatin, H3K27me3-containing
chromatin forms very fast after DNA replication in the more primitive CD34+CD90+ and CD34+CD38 subsets. Induction with
cytokines slows post-replicative accumulation of H3K27me3,
making it similar to that of bulk CD34+ cells. Similar to CD34+
cells, further differentiation accelerates accumulation of postreplicative H3K27me3 in both types of cells (Figures 1B and
5A). The differences in the initial rate of accumulation of
post-replicative H3K27me3 between CD34+, CD34+CD38,
and CD34+CD90+ cells may be explained by the fact that a significant proportion of bulk CD34+ cells likely consists of progenitors with the molecular profile of cells committed to a specific
lineage but unable to further differentiate in the absence of
instructive cytokines. Instead, the H3K27me3-modified chromatin of more primitive CD34+CD38 and CD34+CD90+ progenitors may reflect the undifferentiated status of hematopoietic
stem cells (HSCs) and, upon cytokine treatment, exhibit significant changes in the rate of accumulation of H3K27me3 after
DNA replication. Similar to that detected in bulk CD34+ cells (Figure 2B), G-CSF treatment of CD34+CD38 cells promotes the
accumulation of the lineage-determining TF C/EBPa on nascent
DNA (Figure S4).
We also assessed the loading of H3K27me3 on nascent
DNA of primitive Lin-Sca-1+Kit+ mouse HPCs. Like human
CD34+CD38 cells, these cells exhibited high accumulation of
H3K27me3 on DNA labeled with EdU for only 15 min (Figure S5);
moreover, treatment of Lin-Sca-1+Kit+ cells with recombinant
murine G-CSF for 4 hr induced a state of globally de-condensed,

Figure 3. H3K27me3-Unmodified Post-replicative Chromatin Is
Essential for DNA Binding of Lineage-Determining TFs
(A) Top: accumulation of post-replicative H3K27me3 leads to decreased
recruitment of lineage-determining TFs. Cord blood CD34+ cells were induced
toward myeloid differentiation with G-CSF (left) or M-CSF (middle), or erythroid
differentiation with EPO (right) for 12 hr. During the induction period cells were
left untreated (upper panels) or treated with the GSKJ4 inhibitor of KDMs UTX

and JMJD3 (lower panels). DNA was pulse-labeled with EdU for 15 min and
chased to 1 hr. CAA was performed between nascent DNA (biotin) and C/EBPa
(left), PU.1 (middle), or GATA-1 (right). Red, PLA; green, EdU (biotin); blue,
DAPI. Lower panel shows PLA signals only. Bottom: quantification of the results of CAA experiments shown above by counting the number of PLA signals
per EdU-labeled nuclei in 50 cells/each of the three independent experiments.
(B and C) G-CSF-mobilized CD34+ cells were cultured for 24 hr in the presence
of the CC100 cytokine cocktail (CTRL), or with EPO only (EPO) or with EPO
and GSKJ4 (EPO + GSKJ4). (B) Cells were immunostained with antibody
to GATA-1 (red). Blue, DAPI. Lower panel shows GATA-1 signals only.
(C) Western blot analysis with GATA1 and actin antibodies.
(D and E) Effect of UTX/JMJD3 inhibition on EPO-induced erythroid differentiation of CD34+ HPCs. Cells were cultured for 72 hr in the presence of the
CC100 cytokine cocktail (CTRL), in the presence of EPO only (EPO), or in the
presence of EPO only and GSKJ4 (EPO + GSKJ4). (D) Real-time PCR analysis
(performed in triplicate) of GATA-1 target genes in untreated EPO-, or EPO plus
GSKJ4-treated CD34+CD38+ cells. (E) Erythroid differentiation monitored by
flow cytometry. Error bars represent ± SD. p Values were determined by
Student’s t test. ***p < 0.001.
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Figure 4. C/EBPa Is Recruited to DNA Only
during Post-replicative Period
(A) Cord blood CD34+ HPCs were labeled with EdU
for 30 min and induced with G-CSF for 24 hr in the
absence (Cont) or presence of 2.5 mM thymidine.
After release from thymidine block, CAA was performed between nascent DNA (biotin) and C/EBPa at
0, 2, and 4 hr. Red, PLA; green, EdU (biotin); blue,
DAPI. Lower panel shows PLA signals only. A graph
below shows quantification of the results of CAA experiments by counting the number of PLA signals per
EdU-labeled nuclei in 50 cells/each of the three independent experiments.
(B) Following DNA labeling with EdU for 30 min and induction with G-CSF, CD34+ HPCs were grown for 24 hr
in the presence of thymidine. Thymidine block was
released for 0, 2, and 4 hr, and cells were labeled for
20 min with BrdU. Cells were double-immunostained for
EdU (green) and BrdU (red). Error bars represent ± SD.
p Values were determined by ANOVA. *p < 0.05.

H3K27me3-unmodified nascent chromatin. However, an 8 hr
treatment of these cells with G-CSF was sufficient to induce
the rapid accumulation of H3K27me3 on nascent DNA. Together,
these data indicate that accumulation of H3K27me3 on nascent
DNA is similar in primitive human and mouse HPCs, although in
the latter cells the kinetics appears to be somewhat faster.
Accumulation of H3K27me3 Is Delayed on Nascent
Chromatin of Repressed Genes
Our results suggest that following induction with cytokines
accumulation of H3K27me3 is globally delayed following DNA
replication. This implies that accumulation of H3K27me3 is
300 Cell Reports 19, 295–306, April 11, 2017

delayed in regulatory regions of repressed
genes that contain H3K27me3 during transcriptional interphases. To examine this,
we analyzed the kinetics of accumulation
of H3K27me3 on nascent DNA at the promoters of several repressed genes by
re-chromatin immunoprecipitation (ChIP)
assays (Francis et al., 2009; Petruk et al.,
2012). Because this type of analysis requires 107 cells per each sample, it is not
feasible to use purified CD34+CD38 cells
in these assays. Thus, we used batches of
CD34+ cells which contain significant proportion of CD38 cells. DNA of uninduced
CD34+ cells and CD34+ cells induced with
EPO was labeled with BrdU for 15 min or
for 15 min followed by a chase to 2 hr.
Cells were induced with EPO for 24 hr
because induction with this cytokine leads
to a longer period of delayed accumulation of H3K27me3 on nascent DNA than
after induction with G-CSF (not shown).
Chromatin was first immunoprecipitated
with antibody to H3K27me3, and in the
next step the purified DNA was immunoprecipitated with antibody to BrdU. ChIP assays at the first immunoprecipitation step demonstrate that four examined genes
contain similar amounts of H3K27me3 at their promoters
before and after EPO induction (Figure 6A), confirming that
they remain repressed during erythroid differentiation (Cui
et al., 2009). In re-ChIP assays, we detected significant accumulation of H3K27me3 on 15 min BrdU-labeled DNA (Figure 6B),
suggesting a fast mode of accumulation of H3K27me3 characteristic for early progenitor cells (Figure 5). Accumulation of
H3K27me3 is significantly delayed at the promoters of all
repressed genes on 15 min of BrdU-labeled DNA following
induction with EPO (Figure 6B). These results confirm at a

Figure 5. H3K27me3-Conatining Nascent Chromatin Undergoes
Dynamic Changes in Cytokine-Treated Primitive HPCs
(A) CD34+ HPCs were labeled with EdU for 15 min. CAA was performed for
H3K27me3 antibody. Cells were then immunostained for CD90 (green) and
EdU (blue).
(B) Induction of CD34+CD38 HPCs with G-CSF (top) or M-CSF (bottom) leads
to de-methylation of H3K27me3. Purified CD34+CD38 HPCs were induced
with G-CSF (upper panels) or M-CSF (lower panels) for 0, 12, and 24 hr. Cells
were labeled with EdU for 15 min. CAA was performed between nascent DNA
(biotin) and H3K27me3 antibodies. Red, PLA; green, EdU (biotin); blue, DAPI.
Lower panel shows PLA signals only. Quantification of the results of CAA
experiments is shown under images and was estimated by counting the
number of PLA signals per EdU-labeled nuclei in 50 cells/each of the three
independent experiments. Error bars represent ± standard deviation. p Values
were determined by ANOVA. *p < 0.05.

gene level that accumulation of H3K27me3 on nascent DNA is
delayed following induction of differentiation of HPCs.
Cytokine Treatment Leads to Induction of H3K27me3
KDMs UTX and JMJD3 in Primitive HPCs
The observed differences in the rate of accumulation of
H3K27me3 in CD34+CD38 cells may depend on changes in
the amounts or the activities of the H3K27-specific methylating
and de-methylating enzymes, such as KMT EZH2 and KDM
UTX, respectively. Thus, we examined the presence of these enzymes on DNA following DNA replication. Similar amounts of the
KMT EZH2 were detected in uninduced CD34+CD38 cells and
in the same cells induced for 12 hr to myeloid differentiation
by G-CSF or M-CSF treatment (Figure 7A). However, UTX was
not detected on DNA in untreated CD34+CD38 cells, but was
detected on DNA of these cells 12 hr following induction with
each cytokine (Figure 7A). These results were confirmed by
several independent assays. Western blot analysis revealed an
increase in the UTX protein in G-CSF- or M-CSF-treated (12 hr)
CD34+CD38, whereas UTX levels did not change after cytokine
treatment of the less primitive CD34+CD38+ progenitors (Figure 7B); compared to high amounts of EZH2 in all CD34+ cells,
UTX was barely detectable by immunofluorescence (Figure 7C),
or by CAA on 1 hr EdU-labeled DNA (Figure 7D) in the nuclei of
more primitive CD90+ cells. Likewise, using CAA, we detected
low amounts of the homologous H3K27me3 KDM JMJD3 on
DNA of the CD90+ cells and an increase in this protein in the
CD90 cells (Figure 7D). Thus, a 12-hr cytokine treatment of
primitive HPCs leads to induction of the KDMs UTX and
JMJD3 proteins and their further accumulation on DNA. This
may explain the switch detected in these cells from the fast to
the slow mode of accumulation of post-replicative H3K27me3
after DNA replication (Figure 5B).
DISCUSSION
Cytokine-induced lineage specification of CD34+ HPCs involves
the recruitment of lineage-determining TFs (e.g., GATA-1 or
C/EBPa) to the regulatory regions of differentiation-related genes
and is accompanied by complex changes in transcriptional programs and chromatin structure (e.g., patterns of H3K4me3 and
H3K27me3 histone marks) (Cui et al., 2009; Lara-Astiaso et al.,
2014; Mercer et al., 2011; Wei et al., 2009). However, it is not
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Figure 6. Kinetics of H3K27me3 Accumulation at Nascent DNA of Specific Genes during Erythroid Differentiation of CD34+ HPCs
(A) ChIP assays with the H3K27me3 antibody.
Uninduced and 24 hr EPO-induced CD34+ cells
were labeled with BrdU for 15 min or 15 min and
chased to 60 min. Chromatin was immunoprecipitated with H3K27me3 and IgG antibodies.
(B) ChIP assays with the BrdU antibody. DNA from
the first immunoprecipitation step with H3K27me3
antibody (A) was denatured and immunoprecipitated with the BrdU antibody. Q-PCR was performed at genes repressed before and after EPO
induction (GPR85, WNT16, HOXB8, HOXB13) and
at a non-repressed control gene (CD11B) (Cui
et al., 2009). Percent of input for re-ChIP experiments was calculated using the amount of material
eluted from the beads following immunoprecipitation with H3K27me3 as 100% input. Data are
represented as mean ± SD of technical replicates
of one of the independent experiments. p Values
were calculated by a one-way ANOVA with Bonferroni’s post hoc test. The statistical significance
was defined as p < 0.05.

known whether binding of TFs to new target genes is a regulated
process and whether it is affected by histone modifications and
the structure of chromatin. Thus, we have a very limited view of
the molecular mechanisms regulating a switch in transcriptional
and epigenetic programs in dividing HPCs as these cells undergo
lineage specification.
In this study, we uncovered a chromatin-based molecular
mechanism of HPCs differentiation toward a specific lineage.
The H3K27me3 mark rapidly associates with nascent DNA in
primitive human CD34+CD38 cells (see model in Figure 7E)
and mouse Lin-Sca-1+Kit+ cells. Upon induction with instructive
cytokines, the global accumulation of H3K27me3 on nascent
DNA is significantly delayed. In line with this, accumulation of
H3K27me3 in nascent chromatin is also globally delayed in
the more differentiated CD34+CD38+ HPCs. Our data suggest
that transition from a more compact, H3K27me3-modified,
to a more de-condensed, H3K27me3-unmodified chromatin
structure, may be explained by the induction of H3K27me3
KDMs UTX and JMJD3 that may efficiently de-methylate this
residue.
Once established, the H3K27-unmodified chromatin exists
for a short period of time at very early stages of differentiation.
During this period, cytokines also induce expression of lineage-specific TFs that quickly associate with DNA (Figure 7E).
The transient H3K27-unmodified chromatin state is essential
for the initial association of these TFs with nascent DNA that occurs at early stages of DNA replication. Remarkably, maintaining
the H3K27me3 repressive mark on nascent chromatin of CD34+
HPCs by pharmacological inhibition of the H3K27me3 demethylases blocks the association of lineage-determining TFs to DNA
and suppresses cytokine-induced erythroid or myeloid differentiation (Figures 3 and S2). Consistent with these findings, conditional knockout of UTX in female mice induces marked depletion
of erythroid progenitors in the bone marrow and of erythrocytes
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in the peripheral blood, in addition to profound thrombocytopenia and relative leukocytopenia (Thieme et al., 2013).
Fast accumulation of the H3K27me3 mark on nascent DNA resumes once CD34+ HPCs becomes committed to a single lineage (Figure 7E); this process may be designed to ensure that
uni-lineage committed progenitors complete their differentiation
program by hindering DNA binding of unwanted TFs that may
antagonize the effect of the lineage-determining TF or cooperatively promote differentiation along a closely related lineage
(Friedman, 2007).
The lineage-determining TFs analyzed in this work belong to
the class of pioneer factors (Iwafuchi-Doi and Zaret, 2014; Zaret
and Carroll, 2011) that are able to overcome the barrier of
chromatin, bind to the so-called L-type chromatin that contains
nucleosomes without many activating or repressive marks
including H3K27me3, and facilitate binding of other essential
TFs (Iwafuchi-Doi and Zaret, 2016). The pioneer property of these
TFs was demonstrated mostly during reprogramming of differentiated cells following ectopic expression of these proteins (Di Stefano et al., 2014; Feng et al., 2008; Heinz et al., 2010; Kulessa
et al., 1995; Xie et al., 2004). However, actively repressed chromatin (R-type), which includes genes marked by H3K27me3, is
not accessible to any TF, including pioneer factors (IwafuchiDoi and Zaret, 2016).
Our work uncovers a chromatin-based mechanism of recruitment to DNA of lineage-determining TFs induced at physiological levels by cytokines during differentiation of hematopoietic
progenitor cell subsets. Based on this model, lineage-determining TFs do not need to overcome the chromatin barrier as
proposed for pioneer factors on L-type chromatin, but gain access to their specific binding sites on a transiently ‘‘open’’ chromatin of nascent DNA. This mechanism of recruitment to DNA of
lineage-determining TFs is not limited to HPCs, as binding to
H3K27-unmethylated post-replicative chromatin is also a feature

Figure 7. Induction of H3K27me3 KDMs UTX and JMJD3 during Lineage Specification
(A) Kinetics of EZH2 (left panels) and UTX (right panels) accumulation during induction of CD34+CD38 HPCs with G-CSF (upper panels) or M-CSF (lower panels).
Purified CD34+CD38 HPCs were induced with G-CSF (left) or M-CSF (right) for 0 and 12 hr. Cells were labeled with EdU for 15 min and chased to 1 hr. CAA was
performed between nascent DNA (biotin) and EZH2 (upper panels) or UTX (lower panel) antibodies. Red, PLA; green, EdU (biotin); blue, DAPI. Lower panel shows
PLA signals only. Graphs represent quantification of the results of CAA experiments shown above by counting the number of PLA signals per EdU-labeled nuclei
in 50 cells/each of the three independent experiments. Error bars represent ± SD. p Values were determined by ANOVA. *p < 0.05.
(B) CD34+CD38 or CD34+CD38+ HPCs were uninduced or induced by treatment with G-CSF or M-CSF. Cells were analyzed by western blotting with antibody to
UTX protein.
(C) CD34+ HPCs were immunostained with antibodies to UTX (red), CD90 (green, indicated by arrows), and EZH2 (blue).
(D) CD34+ HPCs were pulse-labeled with EdU for 1 hr. CAA was performed for UTX and JMJD3 antibodies and EdU (biotin). Cells were then immunostained for
CD90 (green, indicated by arrows) and EdU (blue).
(E) A model for opening of post-replicative chromatin and recruitment of TFs to nascent DNA upon induction of primitive HPCs with lineage-specific cytokines.
Primitive (CD34+CD38 or CD34+CD90+) HPCs exhibit the H3K27me3 repressive mark on post-replicative chromatin; treatment with instructive cytokines induces H3K27me3 demethylase activity (UTX in the model) and expression of lineage-determining TFs. H3K27me3-unmodified post-replicative chromatin allows
binding of lineage-determining TFs to nascent DNA. Upon commitment to unilineage differentiation, H3K27me3 accumulates fast on nascent DNA preventing
binding of additional TFs thus restricting transcriptional program and differentiation potential of these cells.
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of TFs promoting lineage-specification in mouse and human
embryonic stem cells (Petruk et al., 2017 [an accompanying paper in Molecular Cell]). Thus, these findings of dynamic changes
in chromatin conformation may provide a molecular explanation
of the biological plasticity of hematopoietic and embryonic stem
cells. Future studies may also provide important insights into
more mechanism-based approaches in treatment of hematopoietic disorders including leukemia.
EXPERIMENTAL PROCEDURES
Induction of HPCs with Different Cytokines
Human CD34+CD38+ cells were maintained in SFEM (Stem Cell Technologies)
enriched with CC100 cocktail of cytokines (SCF, 100 ng/mL; FLT3L, 100 ng/mL;
IL-3, 20 ng/mL; IL-6, 20 ng/mL; Stem Cell Technologies) for 12 hr after thawing.
Cells were then washed to eliminate the CC100 cytokines and were plated at a
concentration of 106 cells/mL in SFEM with the addition of either 100 ng/mL of
G-CSF (Peprotech) or 10,000 U/mL of M-CSF (R&D Systems) to induce myeloid
differentiation, or 10 ng/mL of EPO (Peprotech) to induce erythroid differentiation. The cytokines were re-added at every medium-change.
Purification of CD34+CD38 HPCs
Peripheral blood human CD34+ cells mobilized by G-CSF treatment were
sorted 12 hr after thawing on the BD FACS Aria machine, according to the
expression of CD38 surface marker. Purified CD34+CD38 were induced to
myeloid lineage with G-CSF or M-CSF and used in CAA and western blotting
experiments with antibodies to H3K27me3, EZH2, and UTX.
Purification of Lin-Sca-1+Kit+ Cells
C57BL/6J mice (Jackson Laboratory, stock number 000664) were kept in a
pathogen-free facility and euthanized in accordance with the Institutional
Animal Care and Use Committee (IACUC) of Thomas Jefferson University.
Femoral, tibial, and pelvic bones of 6- to 8-week-old mice were dissected
from surrounding muscles and ground in PBS 2% fetal bovine serum (FBS) using
a mortar and pestle. Bone marrow cells were filtered through a 40 mm nylon mesh
cell strainer (Fisherbrand), and erythrocytes were lysed in 0.8% ammonium chloride (STEMCELL Technologies). Cells were washed twice before staining with
PerCP-Cy 5.5 mouse lineage antibody cocktail (BD Pharmingen), PE rat antimouse Ly-6A/E (Sca1, BD Pharmingen), and fluorescein isothiocyanate (FITC)
rat anti-mouse CD117 (Kit, BD Pharmingen). Lin-Sca1+Kit+ (LSK) cells were
sorted using a MoFlo AstriosEQ (Beckman Coulter) and then seeded at 1 3
106/mL in SFEM (STEMCELL Technologies) supplemented with SCF (12.5 mg),
FLT3L (12.5 mg), interleukin (IL)-3 (5 mg), and IL-6 (5 mg) (all from Gemini) for 20 hr.
Analysis of Protein Association with Nascent DNA by CAA
CAA experiments were performed as described before (Petruk et al., 2012,
2013) with small variations. HPCs were pulse-labeled with 5 mM EdU. Approximately 20,000 cells per each condition were harvested and cytospun (750 rpm
for 5 min) on polylysine-coated slides (Polyscience), fixed with 4% formaldehyde, permeabilized in 0.25% Triton, and subjected to Click-iT reaction (Invitrogen) to conjugate biotin to EdU. Cells were incubated with mouse antibody
to biotin and rabbit antibodies to the protein of interest. The PLA reaction was
performed according to the manufacturer (Olink) and as described before.
Following PLA, EdU was detected by immunostaining with Alexa Fluor 488conjugated anti-biotin mouse antibody.
Re-ChIP with BrdU-Labeled DNA
For each experiment, 8–10 3 106 CD34+ peripheral blood G-CSF-mobilized
cells were either not induced or induced for 24 hr with EPO. Undifferentiated
and induced cells were labeled with 75 mM BrdU (Sigma-Aldrich) for 15 min or
15 min followed by chase for 2 hr and fixed with 1% formaldehyde for 10 min
at room temperature. Chromatin was purified and treated with micrococcal
nuclease using Simple ChIP Chromatin IP Kit (Cell Signaling). After treatment,
chromatin was immunoprecipitated first with antibody to H3K27me3 (Millipore)
or rabbit IgG (Jackson ImmunoResearch). This material was analyzed as con-
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ventional ChIP. Following purification, DNA was further immunoprecipitated
with antibody to BrdU and used for PCR amplification (re-ChIP). The detailed
protocol is described in Francis et al. (2009) and Petruk et al. (2012). All PCR reactions were performed with an Applied Biosystems StepOne Real-Time PCR
system. Genes containing H3K27me3 at their promoters (GPR85, WNT16,
HOXB8, HOXB13) and a control-activated gene (CD11B) before and after cytokine induction were selected according to (Cui et al., 2009).
Treatment with Thymidine
To control the efficiency of the thymidine block of DNA replication,
CD34+CD38+ cord blood cells were labeled with EdU for 30 min, induced by
G-CSF, and grown for 24 hr in the presence of 2 mM thymidine. Following
release from thymidine block for 2 or 4 hr, cells were labeled with BrdU to
monitor resumption of DNA synthesis. Following ‘‘Click-iT’’ reaction to conjugate biotin to EdU (Petruk et al., 2012), cells were fixed in 4% formaldehyde,
denaturated in 2N HCL for 30 min for detection of BrdU, and immunostained
with antibodies to biotin and BrdU. To perform thymidine block analysis
for recruitment of C/EBPa to DNA, nascent DNA of CD34+CD38+ cells was
labeled for 30 min with EdU, and then cells were induced with G-CSF and
grown for 24 hr in the presence of 2 mM thymidine. Thymidine was removed
by three washes with SFEM, cells were grown for the additional 2 or 4 hr
and were cytospun on slides, fixed with 4% formaldehyde, and permeabilized
in 0.25% Triton. Following ‘‘Click-iT’’ reaction, CAA was performed between
nascent DNA (biotin) and C/EBPa as described above.
Treatment with GSKJ4
CD34+CD38+ cells (cord blood or peripheral blood G-CSF-mobilized) were
induced toward myeloid or erythroid differentiation for 12–72 hr in the presence of 5 mM GSKJ4 (Tocris Bioscience) dissolved in DMSO. In control experiments, cells were incubated with the same concentration of DMSO without
GSKJ4. Erythroid differentiation was monitored after 72 hr by flow cytometry
analysis detection of CD36 and glycophorin A/GYPA/CD235a double-positive
cells. Expression of GATA-1-regulated genes was analyzed at 48 hr by realtime PCR with the following primers: GATA-1 forward 50 -GCTACACCAG
GTGAACCGGC-30 , reverse 50 -CAGACTGGAGCCCCGTTTCT-30 ; ALAS2 forward 50 -TTCAAGACTGTGAACCGCTG-30 , reverse 50 -GCTCATGCCCAGGT
AATCAT-30 , GYPA forward 50 -GGGTGATGGCTGGTGTTATTGG-30 , reverse
50 -AAAGGCACGTCTGTGTCAGG-30 ; and ABCB10 forward 50 -CGGAGGC
CCGGAAGCTC-30 , reverse 50 -TTCCCCAGGAAGAAAGGGGC-30 .
Granulocytic differentiation was monitored by flow cytometry analysis of
CD33 and CD15 levels (at 72 hr post-G-CSF treatment) and by expression
of C/EBPa-regulated genes (at 72 hr post G-CSF treatment) detected by
real-time PCR with the following primers: CEBPE (C/EBPepsilon) forward
50 -CCAGCCGAGGCAGCTACAAT-30 , reverse 50 -CAAAGGGGCCTTGAGAAC
GC-30 ; MPO (myeloperoxidase) forward 50 -TCTCCTCACCAACCGCTCAG-30 ,
reverse 50 -CCGGTTGTGCTCCCGAAGTA-30 ; ELANE (neutrophilic elastase)
forward 50 -CTGGGAGCCCATAACCTCTCG-30 , reverse 50 -CGTTGAGCTGG
AGAATCACGA-30 ; and S100A8 (calgranulin A) forward 50 -ATATCAGGAAA
AAGGGTGCAGACG-30 , reverse 50 -GCTGCCACGCCCATCTTTAT-30 . Realtime PCR data were normalized for expression of GAPDH detected with the
following primers forward 50 -CCCATCCCATCTTCCAGGAG-30 and reverse
50 -CTTCTCCATGGTGGTGAAGACG-30 .
Antibodies
Anti-human CD34-PE (Miltenyi Biotec #130-081-002) and anti-human CD38APC (Miltenyi Biotec #130-092-261) were used to analyze the percentage of
CD34+ and CD38+ populations. Anti-human CD15-PE-Cy7 (BD Pharmingen
#560827), CD33-PE (BD Pharmingen #555450), CD11b-APC (BD Pharmingen
#561015), and CD14-PE (BD Pharmingen #555398) were used to test the percentage of cells positive for granulocytic and macrophage differentiation
markers. CD235a-Pe-Cy5 (BD Pharmingen #561776) and CD36-PE (BD Pharmingen #561821) were used to assess erythroid differentiation. Cells were
incubated with PBS + 1% BSA to prevent antibodies’ non-specific binding
and then stained with fluorochrome-conjugated antibodies for 15 min at
room temperature. Cytofluorimetric analysis was performed on LSRII flow
cytometer (BD Bioscience, USA). For CAA and immunostaining, the following
antibodies were used: anti-C/EBP (1:200, Abcam); anti-PU.1 (1:100, Santa

Cruz); anti-GATA-1 (1:400, Cell Signaling); anti-H3K27me3 (1:2500, Millipore);
mouse anti-biotin (1:1,000, Jackson ImmunoResearch); UTX (1:400, Thermo
Fisher Scientific); EZH2 (1:400, Cell Signaling); JMJD3 (1:200, Abgent); BrdU
(1:200, BD Bioscience); and CD90 (1:100, R&D Systems).
Statistical Analysis
For CAA experiments and re-ChiP experiment, p values were calculated by a
one-way ANOVA with Bonferroni’s post hoc test. The statistical significance
was defined as p < 0.05.
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